ClinicalTrials.gg
Status unknownNCT04167982Updated Nov 24, 2020

Efficacy and Safety of Painless 5-aminolevulinic Acid Photodynamic Therapy for Moderate and Severe Acne Vulgaris

An interventional study of Aminolevulinic acid photodynamic therapy and Oral conventional-dose isotretinoin in Acne, sponsored by Shanghai Dermatology Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2020-11-24.

Sponsored by Shanghai Dermatology Hospital · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Nov 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Acne Vulgaris with a site in China — 8 open to participants now, 10 under way, 2 of them phase 3. Acne Vulgaris · China.

Planned enrollment
10th of 33
234 · median 100
Started
2020
with 2 others
No phase
14 of 35
3 open now
Registered
11th of 35
by date
Lead sponsor
4 of 35
Shanghai Dermatology Hospital

Among the 35 studies in Acne Vulgaris with a site in China, this one is the 10th largest by planned enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2020, is one of 14 with no phase, and was the 11th registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

8 of the 35 studies in Acne Vulgaris with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Acne Vulgaris with a site in China, or all of them as a file.
02

Study summary

This study is being done to compare a new, continuous illumination and short Incubation time regimen of 5-aminolevulinic acid photodynamic therapy (painless ALA- PDT) to low-dose and conventional dose of oral isotretinoin for treatment of moderate or severe acne vulgaris. The hypothesis is that the painless ALA- PDT will be equally or more efficacious as oral isotretinoin, and taking effect more quickly with less adverse effect.

03

Conditions studied

  • Acne

Browse trials for

Keywords

  • Acne
  • low-dose isotretinoin
  • Photodynamic Therapy
  • Painless
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosed with moderate to severe acne
  • Male and female patients of age between 18-40 years old
  • All patients read the instructions of the subject, willing to follow the program requirements
  • No other topical treatment received within 2 weeks prior to enrollment
  • No systemic treatment was given within 4 weeks prior to enrollment
  • Patients were unsuitable for other treatments for various reasons and signed when they had informed other alternatives and agreed to take pictures of the lesion

Exclusion criteria

Exclusion Criteria:

  • Those who did not complete the
  • The lesions belongs to any of the following conditions: There is damage and inflammation, which may lead to the drug entering the open wound
  • Patients with skin photoallergic diseases, porphyria
  • Known to have a history of allergies to test drugs (porphyrins) and their chemically similar drugs
  • Patients with other obvious diseases that may affect the evaluation of efficacy
  • Scars or patients with a tendency to form scars
  • Known to have severe immune dysfunction, or long-term use of and
  • Severe heart, liver, kidney disease; with hereditary or acquired coagulopathy
  • Those with severe neurological, psychiatric or endocrine diseases
  • Women who are pregnant, breast-feeding or using inappropriate -Those with a history of drug abuse; those who have participated in other drug clinical trials within 4 weeks before treatment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
234 participants (estimated)

Study arms

  • Experimental
    Painless Photodynamic Therapy(P-PDT) group

    The painless photodynamic therapy group underwent narrow-band light-emitting diode (LED) irradiation (630 nm; 150 J/cm2) after applying 5% 5-aminolevulinic acid(ALA) cream for 30min. A repeat treatment was administered once weekly for a maximum of 5 times. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and after treatment.

    Procedure: Aminolevulinic acid photodynamic therapy

  • Active comparator
    conventional-dose isotretinoin group

    Patients in the conventional-dose isotretinoin group were given oral isotretinoin 0.5 mg/kg daily for 6 months, and the cumulative dose was 90 mg/kg. Time for subsequent visit: once every two weeks during the 1st and 2nd months, monthly during 3rd to 6th months. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and 2nd , 6th months after treatment.

    Drug: Oral conventional-dose isotretinoin

  • Active comparator
    low-dose isotretinoin group

    Patients in the low-dose isotretinoin group were given oral isotretinoin 0.2 mg/kg daily for 6 months, and the cumulative dose was 36 mg/kg. Time for subsequent visit: once every two weeks during the 1st and 2nd months, monthly during 3rd to 6th months. Blood samples, urine routine, blood biochemistry and electrocardiogram were performed before treatment and 2nd , 6th months after treatment.

    Drug: Oral low-dose isotretinoin

Interventions

  • ProcedureAminolevulinic acid photodynamic therapy

    Aminolevulinic acid photodynamic therapy

  • DrugOral conventional-dose isotretinoin

    Conventional-dose isotretinoin

  • DrugIsotretinoinStudies of IsotretinoinIsotretinoin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    low-dose isotretinoin

06

What researchers measure

Primary outcomes

  1. The clearance rate of Moderate or Severe Acne

    The clearance rate of Moderate or Severe Acne will be measured at 1st month after the last treatment

    Time frame: The clearance rate of Moderate or Severe Acne will be measured at 1st month after the last treatment

Secondary outcomes

  1. Pain assessment

    The pain will be assessed using Visual Analogue Scale (NRS) with a score range of 0-10. The higher the score, the greater the pain, with 0 being no pain and 10 being the most unbearable pain. Pain will be measured at different time points during and after every treatment (including immediately, 1st minute, 3rd minute, 5th minute, 7th minute, 10th minute and 2nd hour, 12th hour, 24th hour and 48th hour after treatment.

    Time frame: immediately, 1st minute, 3rd minute, 5th minute, 7th minute, 10th minute and 2nd hour, 12th hour, 24th hour and 48th hour after treatment

07

Study locations

1 of 1 sites recruiting
  • Lei Shi
    Shanghai, Shanghai 200443, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Clinical study report

Time frame: One year after finishing this study and for permanency

Access criteria: anyone who search pubmed

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Nov 2022, 32 months after the start.

Of 59 non-industry interventional studies with no phase under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 17. This study's planned 32 months is above that.

Counting every sponsor, half of 122 studies reached it within 9 months; a quarter within 4 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2019
First posted
Nov 19, 2019
StartActual
Mar 28, 2020
Primary completionEst.
Nov 30, 2022
CompletionEst.
Nov 30, 2022
Last update
Nov 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04167982
Lead sponsor
Shanghai Dermatology Hospital
Collaborators
Huadong Hospital, RenJi Hospital
Responsible party
Sponsor
First posted
Nov 19, 2019
Start date
Mar 28, 2020
Primary completion
Nov 30, 2022 (estimated)
Completion
Nov 30, 2022 (estimated)
Last update
Nov 24, 2020

Study contacts

Lei Shi, MD PhD
Contact
leishinsh@163.com
18017336512
Linglin Zhang, MD
Contact
zhangll363@126.com
180173336872
Xiuli Wang, MD PhD
study chair · Shanghai Skin Disease Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion